Zimmer Biomet Holdings, Inc.

Valuation Analysis

About the Company

Zimmer Biomet Holdings, Inc. en bref

Zimmer Biomet Holdings, Inc. (ZBH) is currently trading at 76,74 € with a market capitalization of 14,8 Md €. The trailing P/E ratio stands at 22.81x, with a forward P/E of 9.79x. The 52-week range spans from 68,97 € to 94,40 €; the current price is 18.7% below the yearly high. Year-over-year revenue growth stands at +9.3%. The net profit margin stands at 9.05%.

💰 Dividende

Zimmer Biomet Holdings, Inc. pays an annual dividend of 0,84 € per share, representing a yield of 1.09%. The payout ratio stands at 24.87%.

📊 Avis des analystes

20 analystes évaluent Zimmer Biomet Holdings, Inc. (ZBH) au consensus : Conserver. L'objectif de cours moyen est de 86,04 €, soit un potentiel de +12.12% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 72,36 € à 113,33 €.

Zimmer Biomet Holdings, Inc. : la thèse d'investissement en détail

Zimmer Biomet Holdings, Inc. (ZBH) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 34.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 70.18%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valorisation en contexte

With a PEG ratio of 0.63, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 9.45x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 9.79x is meaningfully below the trailing 22.81x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (5.92%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Zimmer Biomet Holdings, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.